190 related articles for article (PubMed ID: 7715542)
1. Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma.
Goorin A; Strother D; Poplack D; Letvak LA; George M; Link M
Med Pediatr Oncol; 1995 Jun; 24(6):362-7. PubMed ID: 7715542
[TBL] [Abstract][Full Text] [Related]
2. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
[TBL] [Abstract][Full Text] [Related]
3. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
[TBL] [Abstract][Full Text] [Related]
4. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
5. An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
Rosen G
Cancer Treat Res; 1993; 62():49-54. PubMed ID: 8096759
[No Abstract] [Full Text] [Related]
6. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
7. Safety of delayed leucovorin "rescue" following high-dose methotrexate in children.
Camitta BM; Holcenberg JS
Med Pediatr Oncol; 1978; 5(1):55-9. PubMed ID: 370536
[TBL] [Abstract][Full Text] [Related]
8. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
9. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
Cohen IJ
Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
[TBL] [Abstract][Full Text] [Related]
10. Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study.
Bacci G; Gherlinzoni F; Picci P; Van Horn JR; Jaffe N; Guerra A; Ruggieri P; Biagini R; Capanna R; Toni A
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1337-45. PubMed ID: 3493903
[TBL] [Abstract][Full Text] [Related]
11. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.
Goorin AM; Schwartzentruber DJ; Devidas M; Gebhardt MC; Ayala AG; Harris MB; Helman LJ; Grier HE; Link MP;
J Clin Oncol; 2003 Apr; 21(8):1574-80. PubMed ID: 12697883
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.
Delepine N; Delepine G; Cornille H; Brion F; Arnaud P; Desbois JC
Anticancer Res; 1995; 15(2):489-94. PubMed ID: 7763028
[TBL] [Abstract][Full Text] [Related]
13. [High-dose methotrexate/leucovorin adjuvant chemotherapy of osteogenic sarcoma: biochemical effects in DNA-synthesis of bone marrow cells (author's transl)].
Sauer H; Wilmanns W
Blut; 1978 Jun; 36(6):357-61. PubMed ID: 306851
[TBL] [Abstract][Full Text] [Related]
14. [The results of using high-dose methotrexate in treating osteogenic sarcoma].
Perevodchikova NI; Eremina LA; Manziuk LV; Siniukov PA; Fedenko AN; Singin AS; Moldovanova LK
Vopr Onkol; 1990; 36(6):667-71. PubMed ID: 2378085
[TBL] [Abstract][Full Text] [Related]
15. Preoperative administration of high-dose methotrexate for osteosarcoma.
Chan KW; Knowling MA; Duncan CP; Morton KS
Can J Surg; 1984 May; 27(3):305-7, 309. PubMed ID: 6586272
[TBL] [Abstract][Full Text] [Related]
16. Osteosarcoma in adolescents and young adults: new developments and controversies. The Childrens Cancer Group (CCG) studies.
Miser JS; Krailo M
Cancer Treat Res; 1993; 62():287-91. PubMed ID: 7682089
[No Abstract] [Full Text] [Related]
17. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
18. Cerebral arterial disturbances in a transient encephalopathy induced by methotrexate.
Follezou JY; Chauveinc L; Guerin JM
Med Oncol Tumor Pharmacother; 1993; 10(4):181-3. PubMed ID: 8164455
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.
Rosen G; Suwansirikul S; Kwon C; Tan C; Wu SJ; Beattie EJ; Murphy ML
Cancer; 1974 Apr; 33(4):1151-63. PubMed ID: 4544836
[No Abstract] [Full Text] [Related]
20. "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.
Von Hoff DD; Rozencweig M; Louie AC; Bender RA; Muggia FM
Cancer Treat Rep; 1978 Feb; 62(2):233-5. PubMed ID: 305823
[No Abstract] [Full Text] [Related]
[Next] [New Search]
